Maple Grove, Minn.-based EmboMedics has raised $860,000 in equity, and the Series A funding will go mainly toward research and development of its resorbable embolization material, according to a MedCity News report.
The company plans on using the solution as an interventional radiology treatment for men's prostates, to shrink uterine fibroid tumors and in coordination with chemotherapy. The company will use the solution as a platform for future products. EmboMedics plans to have submitted its first generation device for 510(k) clearance by the end of 2014, according to the report.
Boston Scientific Looks to Expand Chinese Presence
Supply Chain Efficiency Improved With Inventory Management Intervention
The company plans on using the solution as an interventional radiology treatment for men's prostates, to shrink uterine fibroid tumors and in coordination with chemotherapy. The company will use the solution as a platform for future products. EmboMedics plans to have submitted its first generation device for 510(k) clearance by the end of 2014, according to the report.
More Articles on Supply Chain:
Medline Launches New Products CatalogBoston Scientific Looks to Expand Chinese Presence
Supply Chain Efficiency Improved With Inventory Management Intervention